echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: Summary Overview and Outlook 9 | First-line treatment options for colorectal cancer

    ASCO 2021: Summary Overview and Outlook 9 | First-line treatment options for colorectal cancer

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Of colorectal cancer (Colorectal cancer, CRC) is one of the most common malignant tumor, the incidence and mortality of cancer were highest in the top five.


    Of colorectal cancer (Colorectal cancer, CRC) is one of the most common malignant tumor, the incidence and mortality of cancer were highest in the top five.


    Metastatic colorectal cancer health index scale

    Between March 2014 and March 2020, 254 patients were randomly assigned (127 capecitabine group and 127 AM group).


    Although there is strong evidence that maintenance therapy can prolong PFS, OS is still unaffected.


    After metastatic colorectal cancer ,

    Original source:

    asco.


    asco.
    org/record/195966/abstract" target="_blank" rel="noopener">https://meetinglibrary.
    asco.
    org/record/195966/abstract

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.